The current standard-of-care (SOC) practice for defining the clinical target volume (CTV) for radiation therapy (RT) in patients with glioblastoma still employs an isotropic 1–2 cm expansion of the T2-hyperintensity lesion, without considering the heterogeneous…
Continue Reading
Breakthrough Cancer Treatment Receives IDE Approval
Alpha Tau Medical Ltd. has achieved a significant milestone in cancer treatment innovation. The FDA has granted an Investigational Device Exemption (IDE) for a pilot study using their revolutionary…
Intratumoral heterogeneity poses a significant challenge to the diagnosis and treatment of recurrent glioblastoma. This study addresses the need for non-invasive approaches to map heterogeneous landscape of histopathological alterations throughout the entire lesion for…
Continue Reading
Researchers at Northwestern University have trailed an implanted ultrasound device in patients, which is used in combination with microbubbles to transiently open pores in the blood brain barrier, allowing chemo drugs to enter. We…
Continue Reading
